rheumatoid arthritis treatment landscape - Covance

2 downloads 164 Views 5MB Size Report
ENROLLMENT WITH EVIDENCE-BASED APPROACHES ... Covance Inc., headquartered in Princeton, NJ, USA is the drug development
RHEUMATOID ARTHRITIS TREATMENT LANDSCAPE

Overcome Your Pain Points With an Experienced and Trusted Partner THERE REMAINS SIGNIFICANT UNMET NEED IN RA There is no cure

Biologic administration is often inconvenient and expensive

Safety of RA treatments, particularly immunosuppressive drugs, is still a concern

RA INDUSTRY UPDATES A trend towards more aggressive treatment under the "treat to target" strategy Steady market growth due in part to aging population

Movement towards early diagnosis and treatment of patients

Expanded range of treatment options including novel biologics and small molecules

Increasing availability of biosimilars making biologic treatments more accessible Biosimilars to infliximab, etanercept and adalimumab all approved

RA DRUG DEVELOPMENT PAIN POINTS  Increasing demand for patients due to a small percentage participating in trials  Difficulty in identifying investigators and locating patients  Inefficient trial design, eligibility creep and inconsistencies in both subjective and objective trial outcomes  Suboptimal patient retention over long trial periods  Competitive biologics marketplace

COVANCE DRUG DEVELOPMENT SOLUTIONS

Addressing the Pain Points of RA Drug Development

OPTIMIZE STUDY PLANNING AND SPEED PATIENT ENROLLMENT WITH EVIDENCE-BASED APPROACHES Total of >175,000

clinical investigators

Total of >793,000 physicians

Total of >15 billion lab test results

Total of >16,000 protocols

Clinical knowledgebase housing >40% global clinical trial data at any one time TARGET PATIENT POPULATIONS FOR EFFICIENT RECRUITMENT  Clinical trial opt-in patient initiative* currently with >2,572 RA patients  Performance metrics on >1400 Ph II–III RA investigators since 2012  All RA study recruitment timelines achieved since 2012  Specialty inflammatory biomarkers, e.g., GlycA, rheumatoid factor and hCRP *Database of patients that have agreed to be contacted directly about relevant clinical trials

IDENTIFY AND VALIDATE RELEVANT BIOMARKERS  Flexible biomarker team offering feasibility, development, validation and production expertise  >550 assays available in-house Learn more about our drug development solutions at www.covance.com Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world. The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440 Europe / Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588 © Copyright 2017 Covance Inc.

INFCDS004-0817